Truscreen Group Ltd
ASX:TRU

Watchlist Manager
Truscreen Group Ltd Logo
Truscreen Group Ltd
ASX:TRU
Watchlist
Price: 0.015 AUD Market Closed
Market Cap: AU$8.3m

Operating Margin

-157.9%
Current
Declining
by 34.6%
vs 3-y average of -123.3%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-157.9%
=
Operating Income
NZ$-2.4m
/
Revenue
NZ$1.5m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-157.9%
=
Operating Income
AU$-2.4m
/
Revenue
NZ$1.5m

Peer Comparison

Country Company Market Cap Operating
Margin
NZ
Truscreen Group Ltd
NZX:TRU
13.5m NZD
Loading...
US
Abbott Laboratories
NYSE:ABT
184.5B USD
Loading...
US
Intuitive Surgical Inc
NASDAQ:ISRG
180.3B USD
Loading...
US
Boston Scientific Corp
NYSE:BSX
136.2B USD
Loading...
US
Stryker Corp
NYSE:SYK
135.2B USD
Loading...
IE
Medtronic PLC
NYSE:MDT
129B USD
Loading...
US
Becton Dickinson and Co
NYSE:BDX
57.4B USD
Loading...
DE
Siemens Healthineers AG
XETRA:SHL
47.3B EUR
Loading...
US
IDEXX Laboratories Inc
NASDAQ:IDXX
54B USD
Loading...
US
Edwards Lifesciences Corp
NYSE:EW
46.8B USD
Loading...
US
Resmed Inc
NYSE:RMD
37.4B USD
Loading...

Market Distribution

Lower than 96% of companies in New Zealand
Percentile
4th
Based on 306 companies
4th percentile
-157.9%
Low
-1 380.2% — 2.6%
Typical Range
2.6% — 15.6%
High
15.6% — 98.6%
Distribution Statistics
New Zealand
Min -1 380.2%
30th Percentile 2.6%
Median 8.5%
70th Percentile 15.6%
Max 98.6%

Truscreen Group Ltd
Glance View

Market Cap
8.3m AUD
Industry
Health Care

TruScreen Group Ltd. engages in the development, manufacture, and sale of cancer detection device and systems. The firm is engaged in the business of the development, manufacturing and sale of cancer detection devices and systems. Its cervical cancer screening device offers technology in cervical screening, providing detection of precancerous and cancerous cervical cells to help improve the health and well-being of women worldwide. Its real-time cervical cancer technology utilizes a digital wand, which is placed on the surface of the cervix to measure electrical and optical signals from the surrounding tissues. A sophisticated algorithm framework is utilized to detect pre-cancerous change, or cervical intraepithelial neoplasia (CIN), by optical and electrical measurement of cervical tissue. The product offers an approach to cervical screening, resolving ongoing issues with Pap smear (Pap tests), including failed samples, patient follow-up, patient discomfort and the need for supporting laboratory infrastructure.

TRU Intrinsic Value
0.009 AUD
Overvaluation 40%
Intrinsic Value
Price
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-157.9%
=
Operating Income
NZ$-2.4m
/
Revenue
NZ$1.5m
What is Truscreen Group Ltd's current Operating Margin?

The current Operating Margin for Truscreen Group Ltd is -157.9%, which is below its 3-year median of -123.3%.

How has Operating Margin changed over time?

Over the last 3 years, Truscreen Group Ltd’s Operating Margin has increased from -180.9% to -157.9%. During this period, it reached a low of -180.9% on Aug 30, 2022 and a high of -83.7% on Sep 30, 2024.

Back to Top